This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for First Tracks Biotherapeutics's Median PS Value or its related term are showing as below:
HAM:B43's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.65 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
First Tracks Biotherapeutics (HAM:B43) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
First Tracks Biotherapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
32.00
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Median PS Value Related Terms
First Tracks Biotherapeutics Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Median PS Value Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Median PS Value
0.00
0.00
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Median PS Value
0.00
0.00
HAM:B43 vs ALT, RGNX, MDXG: Median PS Value Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported annually, GuruFocus uses latest annual data as the TTM data. First Tracks Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics (HAM:B43) has a Median PS Value of €0.00 as of Jul. 13, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 278 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' Median PS Value too high?
First Tracks Biotherapeutics' current Median PS Value is €0.00. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Median PS Value compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 278 companies for Median PS Value. This places First Tracks Biotherapeutics in the lower half of its industry. The industry median Median PS Value is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Median PS Value of €0.00. The current Median PS Value is €0.00. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Median PS Value is €0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score
Get the complete analysis for HAM:B43
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:B43 has been successfully added to your 